Article
Virology
Jing Zeng, Xiuqun Zhang, Lin Jia, Yongfeng Wu, Yakun Tian, Yulin Zhang
Summary: Both LMR (lymphocyte-to-monocyte ratio) and PLR (platelet-to-lymphocyte ratio) have been found to be prognostic indicators in patients with AR-DLBCL (AIDS-related diffuse large B-cell lymphoma). Lower LMR is independently associated with poorer overall survival in these patients.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Article
Dermatology
Ji Yun Lee, Minsu Kang, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Kyoung-Ho Song, Eu Suk Kim, Hong Bin Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jong-Seok Lee, Jeong-Ok Lee
Summary: This study found that PCP prophylaxis is highly effective in preventing PCP infection in DLBCL patients undergoing R-CHOP treatment, which can guide prevention strategies for PCP.
Article
Oncology
Yaxiao Lu, Jingwei Yu, Wenchen Gong, Liping Su, Xiuhua Sun, Ou Bai, Hui Zhou, Xue Guan, Tingting Zhang, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Bin Meng, Xiubao Ren, Xianhuo Wang, Huilai Zhang
Summary: The study aimed to evaluate the prognostic value of peripheral blood T lymphocyte subsets in FL patients and develop a predictive model (ICPI) for PFS. The ICPI demonstrated improved prognostic performance and could guide personalized therapy for patients treated with R-CHOP/CHOP chemotherapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Hematology
Ciara L. Freeman, Kerry J. Savage, Diego R. Villa, David W. Scott, Line Srour, Alina S. Gerrie, Maura J. Brown, Graham W. Slack, Pedro Farinha, Brian Skinnider, James Morris, Francois Benard, Christina Aquino-Parsons, Andrea Lo, Tom Pickles, Don C. Wilson, Petter Tonseth, Joseph M. Connors, Laurie H. Sehn
Summary: This study analyzed patients with advanced-stage DLBCL who received at least 6 cycles of R-CHOP treatment, with PET-guided selective administration of consolidative RT showing similar outcomes in PET-POS patients to those of PET-NEG patients. The use of F-18-fluorodeoxyglucose-PET can reliably guide selective administration of consolidative RT, even in patients with initially bulky disease.
Review
Pharmacology & Pharmacy
Daniele Lavacchi, Ida Landini, Gabriele Perrone, Giandomenico Roviello, Enrico Mini, Stefania Nobili
Summary: This review discusses the current research status on molecular biomarkers predictive of DLBCL prognosis and the issue of variability in response to DLBCL drug treatment. It focuses on single nucleotide polymorphisms (SNPs) that are suggested to play a role in the response to R-CHOP, based on candidate gene approaches or genome-wide association studies (GWAS).
PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Oncology
Yan Qin, Haizhu Chen, Peng Liu, Changgong Zhang, Jianliang Yang, Lin Gui, Xiaohui He, Liqiang Zhou, Shengyu Zhou, Shiyu Jiang, Hongxin Jiang, Yuankai Shi
Summary: Limited data about the prognostic significance of BCL2 mutations and BCL2 copy number variations in diffuse large B-cell lymphoma (DLBCL) are available. This study aimed to comprehensively describe BCL2 genetic alterations in DLBCL patients, and examine correlation of BCL2, TP53 and other genetic alterations with outcomes in patients treated with R-CHOP. The presence of BCL2 alterations, especially BCL2 gain/amplifications (BCL2GA/AMP) and TP53 mutations, were significantly associated with inferior outcomes in DLBCL patients treated with R-CHOP, independently of the International Prognostic Index (IPI).
CANCER BIOLOGY & MEDICINE
(2022)
Article
Oncology
Zola Musimar, Mtonga Mpetani, Jeremy S. Abramson, Bruce A. Chabner, Zainab Mohamed
Summary: This retrospective cohort study found that treatment of DLBCL with R-CHOP, including rituximab, can achieve good outcomes in resource-limited settings. In this HIV-negative patient cohort, poor performance status was the most important adverse prognostic factor.
Article
Oncology
Joo Y. Song, Anamarija M. Perry, Alex F. Herrera, Lu Chen, Pamela Skrabek, Michel R. Nasr, Rebecca A. Ottesen, Janet Nikowitz, Victoria Bedell, Joyce Murata-Collins, Yuping Li, Christine McCarthy, Raju Pillai, Jinhui Wang, Xiwei Wu, Jasmine Zain, Leslie Popplewell, Larry W. Kwak, Auayporn P. Nademanee, Joyce C. Niland, David W. Scott, Qiang Gong, Wing C. Chan, Dennis D. Weisenburger
Summary: Detailed genomic analysis of 87 cases of GCB DLBCL identified four distinct biological subgroups with different survivals. A practical schema was proposed to risk-stratify patients with GCB DLBCL and to identify high-risk patients for new and innovative therapies.
CLINICAL CANCER RESEARCH
(2021)
Review
Nutrition & Dietetics
Xin-Tian Xu, Dong-Liang He, Meng-Xing Tian, Hui-Jing Wu, Xin Jin
Summary: Sarcopenia is a negative predictor for prognosis in DLBCL patients.
FRONTIERS IN NUTRITION
(2022)
Article
Oncology
Yu Zhang, Jingjing Xiang, Xianfu Sheng, Ni Zhu, Shu Deng, Junfa Chen, Lihong Yu, Yan Zhou, Chenjun Lin, Jianping Shen
Summary: The study shows that CHOP and R-CHOP treatments potentiate the anti-tumor properties of macrophages by suppressing AKT signaling, with GM-CSF further enhancing their effects.
CANCER CELL INTERNATIONAL
(2021)
Article
Oncology
Grzegorz S. Nowakowski, Annalisa Chiappella, Randy D. Gascoyne, David W. Scott, Qingyuan Zhang, Wojciech Jurczak, Muhit Ozcan, Xiaonan Hong, Jun Zhu, Jie Jin, David Belada, Juan Miguel Bergua, Francesco Piazza, Heidi Mocikova, Anna Lia Molinari, Dok Hyun Yoon, Federica Cavallo, Monica Tani, Kazuhito Yamamoto, Koji Izutsu, Koji Kato, Myron Czuczman, Sarah Hersey, Adrian Kilcoyne, Jacqueline Russo, Krista Hudak, Jingshan Zhang, Steve Wade, Thomas E. Witzig, Umberto Vitolo
Summary: The ROBUST study aimed to compare the efficacy of lenalidomide plus R-CHOP with placebo/R-CHOP in previously untreated ABC-type DLBCL. While the primary end point of progression-free survival (PFS) was not met in all patients, there were trends favoring R2-CHOP over placebo/R-CHOP in patients with higher-risk disease. The safety profile of R2-CHOP was consistent with individual treatments with no new safety signals.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Hematology
Vincent Camus, Aurelien Belot, Lucie Oberic, David Sibon, Herve Ghesquieres, Catherine Thieblemont, Christophe Fruchart, Olivier Casasnovas, Jean-Marie Michot, Thierry Jo Molina, Andre Bosly, Clementine Joubert, Corinne Haioun, Emmanuelle Nicolas-Virelizier, Pierre Feugier, Olivier Fitoussi, Richard Delarue, Herve Tilly
Summary: The study evaluated the efficacy and survival of different treatment regimens in DLBCL patients, and found that the results of the RCHOP-14 and R-CHOP21 groups were similar in terms of PFS and OS. However, progression or relapse after second-line chemotherapy led to poor prognosis, highlighting the need for novel approaches in first-line and alternative treatments.
Article
Hematology
D. Al-Sarayfi, M. Brink, M. E. D. Chamuleau, R. Brouwer, R. S. van Rijn, D. Issa, W. Deenik, G. Huls, R. Mous, J. S. P. Vermaat, A. Diepstra, J. M. Zijlstra, T. van Meerten, M. Nijland
Summary: An attenuated chemo-immunotherapy strategy called R-miniCHOP was introduced as a treatment option for elderly frail patients with diffuse large B-cell lymphoma (DLBCL) in the Netherlands. Although it is more tolerable, the reduction of chemotherapy in R-miniCHOP may negatively affect survival compared to the standard treatment R-CHOP. The study found that patients treated with R-miniCHOP had inferior survival outcomes compared to those treated with R-CHOP.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Hematology
Annalisa Arcari, Lugi Rigacci, Alessandra Tucci, Benedetta Puccini, Sara Veronica Usai, Federica Cavallo, Alberto Fabbri, Monica Balzarotti, Sabrina Pelliccia, Stefano Luminari, Elsa Pennese, Vittorio Ruggero Zilioli, Abdurraouf Mokhtar Mahmoud, Gerardo Musuraca, Dario Marino, Roberto Sartori, Barbara Botto, Guido Gini, Manuela Zanni, Stefan Hohaus, Giuseppe Tarantini, Leonardo Flenghi, Monica Tani, Alice Di Rocco, Michele Merli, Daniele Vallisa, Chiara Pagani, Luca Nassi, Daniela Dessi, Simone Ferrero, Emanuele Cencini, Patrizia Bernuzzi, Caterina Mammi, Luigi Marcheselli, Valentina Tabanelli, Michele Spina, Francesco Merli
Summary: R-CHOP is the commonly used treatment for DLBCL, but it has cardiotoxicity in older patients. Substituting doxorubicin with non-PEGylated liposomal doxorubicin (R-COMP) may reduce cardiac events, but its efficacy has not been proven in prospective trials. This study suggests that R-COMP is a potential treatment for older DLBCL patients with intermediate or high-risk EPI, even in the presence of baseline cardiopathy.
Review
Hematology
Edward J. Bataillard, Chan Yoon Cheah, Matthew J. Maurer, Arushi Khurana, Toby A. Eyre, Tarec Christoffer El-Galaly
Summary: The dilemma of using full or reduced dose intensity of R-CHOP in elderly patients with DLBCL was studied through a systematic review. Lower dose intensity was associated with poorer survival outcomes in most studies, especially in patients aged <80 years. However, elderly patients aged >= 80 years did not show consistent impact on survival outcomes with reduced dose intensity, suggesting full-dose R-CHOP may be more appropriate in this age group. Additional DI-specific randomized trials are needed for further confirmation.
Article
Gastroenterology & Hepatology
Cosmos L. T. Guo, Sunny H. Wong, Louis H. S. Lau, Rashid N. S. Lui, Joyce W. Y. Mak, Raymond S. Y. Tang, Terry C. F. Yip, William K. K. Wu, Grace L. H. Wong, Francis K. L. Chan, James Y. W. Lau, Joseph J. Y. Sung
Summary: The study found that early endoscopy after admission for acute upper gastrointestinal bleeding was associated with better outcomes compared to urgent or late endoscopy, especially in patients with non-variceal bleeding. This suggests that patients with non-variceal AUGIB should receive endoscopy within 24 hours, while also highlighting the importance of prior resuscitation and pharmacotherapy.
Review
Immunology
Cheng Xu, Shu Zhang, Guang-Li Zhu, Kai-Bin Yang, Yuan Zhang, Yan-Ping Mao, Ling-Long Tang, Qing Liu, Ying Huang, Jun Ma
Summary: This study analyzed the disparities in positive results and dissemination patterns of randomized controlled trials (RCTs) in global immuno-oncology (IO). The results showed that positive trials were predominantly sponsored by pharmaceutical companies and focused on immune checkpoint inhibitors (ICIs) and multiple IO therapies. Factors such as recent trial start year, upfront registration, large sample size, strict criteria, and survival endpoints were associated with positive results. Trials from Mainland China had a faster publication timeline of positive results but lacked study diversity or full reporting of negative results compared to US and multinational trials. Positive trials had a shorter publication process, more secondary manuscripts, and better dissemination in high-quality journals compared to negative trials. The study suggests improvements in upfront registration, procedural integrity, and inclusion of rival trials reporting negative results for future IO-related reviews.
INTERNATIONAL REVIEWS OF IMMUNOLOGY
(2023)
Review
Cell Biology
Hongyan Chen, Xiaoting Zhang, Hao Su, Judeng Zeng, Hung Chan, Qing Li, Xiaodong Liu, Lin Zhang, William Ka Kei Wu, Matthew Tak Vai Chan, Huarong Chen
Summary: Sepsis is a life-threatening syndrome caused by immune dysfunction in response to infection. It is a highly heterogeneous condition with complex mechanisms. The immune response to sepsis includes both hyper-inflammatory and immune-suppressive phases, and dysregulated m6A modifications play a significant role in immune cell changes during sepsis.
WILEY INTERDISCIPLINARY REVIEWS-RNA
(2023)
Article
Oncology
Jinglin Zhang, Bonan Chen, Hui Li, Yifei Wang, Xiaoli Liu, Kit Yee Wong, Wai Nok Chan, Aden K. Y. Chan, Alvin H. k Cheung, Kam Tong Leung, Yujuan Dong, Yi Pan, Huixing Ke, Li Liang, Zhaocai Zhou, Jianyong Xiao, Chi Chun Wong, William K. K. Wu, Alfred S. L. Cheng, Brigette B. Y. Ma, Jun Yu, Kwok Wai Lo, Wei Kang, Ka Fai To
Summary: Colorectal cancer (CRC) is a common cancer worldwide, and the tumor microenvironment, specifically cancer-associated fibroblasts (CAFs), plays a crucial role in promoting CRC progression.
JOURNAL OF PATHOLOGY
(2023)
Article
Medicine, General & Internal
Maura Marcucci, Thomas W. Painter, David Conen, Vladimir Lomivorotov, Daniel Sessler, Matthew T. V. Chan, Flavia K. Borges, Kate Leslie, Emmanuelle Duceppe, Maria Jose Martinez-Zapata, Chew Yin Wang, Denis Xavier, Sandra N. Ofori, Michael Ke Wang, Sergey Efremov, Giovanni Landoni, Ydo Kleinlugtenbelt, Wojciech Szczeklik, Denis Schmartz, Amit X. Garg, Timothy G. Short, Maria Wittmann, Christian S. Meyhoff, Mohammed Amir, David Torres, Ameen Patel, Kurt Ruetzler, Joel L. Parlow, Vikas Tandon, Edith Fleischmann, Carisi A. Polanczyk, Andre Lamy, Raja Jayaram, Sergey V. Astrakov, William Ka Kei Wu, Chao Chia Cheong, Sabry Ayad, Mikhail Kirov, Miriam de Nadal, Valery V. Likhvantsev, Pilar Paniagua, Hector J. Aguado, Kamal Maheshwari, Richard P. Whitlock, Michael H. McGillion, Jessica Vincent, Ingrid Copland, Kumar Balasubramanian, Bruce M. Biccard, Sadeesh Srinathan, Samandar Ismoilov, Shirley Pettit, David Stillo, Andrea Kurz, Emilie P. Belley-Cote, Jessica Spence, William F. McIntyre, Shrikant Bangdiwala, Gordon Guyatt, Salim Yusuf, P. J. Devereaux
Summary: This study compared the effects of two different blood pressure management strategies, hypotension-avoidance and hypertension-avoidance, on major vascular complications after noncardiac surgery. The results showed that both strategies had similar incidence of major vascular complications.
ANNALS OF INTERNAL MEDICINE
(2023)
Editorial Material
Gastroenterology & Hepatology
William Ka Kei Wu
Article
Gastroenterology & Hepatology
Ru Zhang, Yunbi Ni, Cosmos L. T. Guo, Rashid N. S. Lui, William W. K. Wu, Joseph J. Y. Sung, Vincent W. S. Wong, Sunny H. Wong
Summary: This study investigated the clinical risk factors of colorectal sessile serrated lesions (SSLs) in Chinese individuals and found that dyslipidemia and diabetes were independent risk factors for SSLs.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Oncology
Jinglin Zhang, Bonan Chen, Yifei Wang, Xiaoli Liu, Huan Yan, Kit Yee Wong, Aden K. Y. Chan, Alvin H. K. Cheung, Chit Chow, Dazhi Xu, Shouyu Wang, Bing Huang, Li Liang, Huixing Ke, Chi Chun Wong, William K. K. Wu, Alfred S. L. Cheng, Jun Yu, Kwok Wai Lo, Ka Fai To, Wei Kang
Summary: This study reveals the oncogenic role of HOXB9 in gastric cancer and identifies CDK6 as its downstream effector. The E2F1-HOXB9/PBX2-CDK6 axis represents a novel mechanism driving gastric carcinogenesis and has prognostic and therapeutic implications.
JOURNAL OF PATHOLOGY
(2023)
Article
Oncology
Shuiqing He, Yan-Ling Wu, Yongxiang Gao, Danjie He, Ying Huang
Summary: This study aimed to evaluate risk stratification and select beneficiaries from concurrent chemotherapy (CCRT) combined with induction chemotherapy (IC) in elderly Nasopharyngeal carcinoma (NPC) patients. Prognostic nomograms were generated based on clinical characteristics and serum biomarkers. The results showed that IC + CCRT significantly improved 5-year survival rates in the high-risk group, specifically in patients younger than 70 years old. TPF and three IC cycles were recommended for treatment.
Article
Oncology
Qing Li, Hung Chan, Wei-Xin Liu, Chang-An Liu, Yunfei Zhou, Dan Huang, Xuelian Wang, Xiaoxing Li, Chuan Xie, Wing Ying-Zhi Liu, Xian-Song Wang, Siu Kin Ng, Hongyan Gou, Liu-Yang Zhao, Winnie Fong, Lanping Jiang, Yufeng Lin, Guijun Zhao, Feihu Bai, Xiaodong Liu, Huarong Chen, Lin Zhang, Sunny Hei Wong, Matthew Tak Vai Chan, William Ka Kei, Jun Yu
Summary: Carnobacterium maltaromaticum is depleted in female patients with colorectal cancer, but supplementation with this bacterium in mice reduces intestinal tumor formation in a female-specific manner. Estrogen increases the attachment and colonization of C. maltaromaticum by promoting the colonic expression of SLC3A2. This bacterium interacts with other gut microbes, such as Faecalibacterium prausnitzii, to produce vitamin D and activate the VDR signaling pathway, which suppresses CRC.
Article
Immunology
Yingzhi Liu, Matthew T. V. Chan, Francis K. L. Chan, William K. K. Wu, Siew C. Ng, Lin Zhang
Summary: This study found that the mortality rate of COVID-19 is associated with the altered composition and functions of the gut microbiome in adults. Higher diversity of gut microbiome and reduction of specific butyrate-producing species were correlated with higher COVID-19 severity.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2023)
Article
Medicine, General & Internal
Xing Kang, Siu-Kin Ng, Changan Liu, Yufeng Lin, Yunfei Zhou, Thomas N. Y. Kwong, Yunbi Ni, Thomas Y. T. Lam, William K. K. Wu, Hong Wei, Joseph J. Y. Sung, Jun Yu, Sunny H. Wong
Summary: Obesity-related gut microbiota plays a significant role in the development of colorectal cancer. Fecal transplantation from obese individuals to mice resulted in increased colon tumor formation, intestinal barrier dysfunction, and activation of oncogenic signaling pathways. The study also identified specific bacteria that may mediate these effects. Modulating the microbiota in obese individuals could potentially prevent or treat obesity-related colorectal cancer.
Editorial Material
Cell Biology
Xichen Bao, Xiaoxing Li, William K. K. Wu, Yanquan Zhang, Liang Zhou
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2023)
Review
Microbiology
Hao Su, Henley Cheung, Harry Cheuk-Hay Lau, Hongyan Chen, Xiaoting Zhang, Na Qin, Yifei Wang, Matthew Tak Vai Chan, William Ka Kei Wu, Huarong Chen
Summary: Understanding the interaction between gut microbiota and host RNA m6A modification provides valuable insights into the mechanisms and therapeutic strategies for cancer. The gut microbiota plays a crucial role in regulating host functions and has a significant impact on human health. Dysbiosis of the gut microbiota is associated with various diseases including cancer. The gut microbiota can influence cancer development through mechanisms such as cell regulation, immune response, and metabolic changes. Aberrant RNA m6A modifications have been shown to play a critical role in cancer development. This review aims to summarize the roles of gut microbiota and RNA m6A modifications in cancer and their potential interactions.
FEMS MICROBIOLOGY REVIEWS
(2023)
Article
Biochemistry & Molecular Biology
Binbin Chen, Ying Huang, Shuiqing He, Peng Yu, Lirong Wu, Hao Peng
Summary: This study reveals that the elevated METTL5/TRMT112 and their mediated m6A modification at the 18S rRNA 1832 site (m6A1832) promote oncogenic transformation in nasopharyngeal carcinoma (NPC). The loss of catalytic activity of METTL5 abolishes its oncogenic functions. Mechanistically, the m6A1832 modification facilitates the assembly of 80S ribosome and promotes the translation of mRNAs with 50 terminal oligopyrimidine (50 TOP) motifs. Furthermore, METTL5 enhances the translation of HSF4b to activate HSP90B1 transcription, which prevents oncogenic mutant p53 (mutp53) protein from degradation and facilitates NPC tumorigenesis and chemoresistance. Overall, this study uncovers an innovative mechanism of rRNA epigenetic modification in cancer.
CELL CHEMICAL BIOLOGY
(2023)